رجوع
نطاق اليوم
KWD 234.25
KWD 238.31
نطاق 52 أسبوعًا
KWD 141.50
KWD 251.71
حجم التداول
7,301,338
متوسط 50 يوم / 200 يوم
KWD 234.14
/
KWD 194.58
الإغلاق السابق
KWD 235.37
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 21.2 | 0.4 |
| P/B | 7.0 | 2.9 |
| ROE % | 35.0 | 3.7 |
| Net Margin % | 28.5 | 3.8 |
| Rev Growth 5Y % | 4.6 | 10.0 |
| D/E | 0.6 | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 228.730
-2.8%
Low: KWD 190.000
High: KWD 265.000
مكرر الربحية المستقبلي
20.4
ربحية السهم المستقبلية
KWD 11.557
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
100 B
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 16.712
KWD 16.101 – KWD 17.188
|
130 B | 2 |
| FY2029 |
KWD 15.057
KWD 14.507 – KWD 15.486
|
120 B | 2 |
| FY2028 |
KWD 13.734
KWD 10.808 – KWD 16.030
|
110 B | 5 |
Insider Trading Activity
Buy ratio (90d)
0.0%
13 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
sell | 4,075 | KWD 247.870 | KWD 1,010,070 |
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
other | 8,150 | KWD 115.670 | — |
| Feb 20, 2026 |
Schmid Timothy
EVP, WW Chair, MedTech
|
sell | 1,322 | KWD 245.660 | KWD 324,763 |
| Feb 9, 2026 |
Broadhurst Vanessa
EVP, Global Corp Affairs
|
grant | 8,594 | — | — |
| Feb 9, 2026 |
Decker Robert J
VP Corporate Controller
|
grant | 2,741 | — | — |
| Feb 6, 2026 |
Mulholland Kristen
EVP, Chief HR Officer
|
other | 14,585 | KWD 101.870 | KWD 1,946,404 |
| Nov 26, 2025 |
MORIKIS JOHN G
Director
|
buy | 1,250 | KWD 206.150 | KWD 257,688 |
| Sep 9, 2025 |
Woods Eugene A.
Director
|
grant | 211 | KWD 178.070 | KWD 37,573 |
| Jul 17, 2025 |
REED JOHN C
EVP, Innovative Medicine, R&D
|
sell | 19,137 | KWD 163.549 | KWD 3,129,830 |
| Jun 10, 2025 |
HEWSON MARILLYN A
Director
|
grant | 322 | KWD 155.230 | KWD 49,984 |
| Apr 24, 2025 |
WEINBERGER MARK A
Director
|
grant | 1,316 | — | — |
| Apr 24, 2025 |
McClellan Mark B.
Director
|
grant | 1,316 | — | — |
| Apr 24, 2025 |
Woods Eugene A.
Director
|
grant | 1,316 | — | — |
النقاط الرئيسية
Revenue grew 4.58% annually over 5 years — modest growth
Earnings grew 90.56% over the past year
ROE of 35.03% indicates high profitability
Net margin of 28.46% shows strong profitability
Generating 19.70B in free cash flow
PEG of 0.21 suggests growth is underpriced
النمو
Revenue Growth (5Y)
4.58%
Revenue (1Y)6.05%
Earnings (1Y)90.56%
FCF Growth (3Y)3.90%
الجودة
Return on Equity
35.03%
ROIC14.83%
Net Margin28.46%
Op. Margin27.17%
الأمان
Debt / Equity
0.59
Current Ratio1.03
Interest Coverage26.36
التقييم
P/E Ratio
21.17
P/B Ratio6.96
EV/EBITDA23.27
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6.05% | Revenue Growth (3Y) | 5.17% |
| Earnings Growth (1Y) | 90.56% | Earnings Growth (3Y) | -12.68% |
| Revenue Growth (5Y) | 4.58% | Earnings Growth (5Y) | 6.45% |
| Profitability | |||
| Revenue (TTM) | 94.19B | Net Income (TTM) | 26.80B |
| ROE | 35.03% | ROA | 13.46% |
| Gross Margin | 72.78% | Operating Margin | 27.17% |
| Net Margin | 28.46% | Free Cash Flow (TTM) | 19.70B |
| ROIC | 14.83% | FCF Growth (3Y) | 3.90% |
| Safety | |||
| Debt / Equity | 0.59 | Current Ratio | 1.03 |
| Interest Coverage | 26.36 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 21.17 | P/B Ratio | 6.96 |
| P/S Ratio | 6.02 | PEG Ratio | 0.21 |
| EV/EBITDA | 23.27 | Dividend Yield | 0.02% |
| Market Cap | 567.34B | Enterprise Value | 595.56B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B |
| EPS (Diluted) | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 |
| Gross Profit | 68.56B | 61.35B | 58.61B | 55.39B | 55.34B |
| Operating Income | 25.60B | 22.15B | 23.41B | 21.01B | 20.94B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B |
| Total Liabilities | 117.67B | 108.61B | 98.78B | 110.57B | 108.00B |
| Shareholders' Equity | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B |
| Cash & Equivalents | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B |
| Current Assets | 55.62B | 55.89B | 53.50B | 55.29B | 60.98B |
| Current Liabilities | 54.13B | 50.32B | 46.28B | 55.80B | 45.23B |